New hope for tough lung cancer cases: trial tests drug duos to extend life
NCT ID NCT05568212
Summary
This study is for people with a specific type of advanced lung cancer (stage III NSCLC) that has returned or gotten worse after they completed a standard treatment plan involving chemotherapy, radiation, and a drug called durvalumab. The trial is testing if adding durvalumab, and another drug called olaparib, to standard chemotherapy helps patients live longer compared to chemotherapy alone. About 176 participants will be assigned by chance to receive different combinations of these treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
RECRUITINGRoma, RM, 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.